Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferati | OTT – Dove Medical Press

Sung-Hwa Sohn,1,* Bohyun Kim,1,* Hee Jung Sul,1 Bo Youn Choi,1 Hyeong Su Kim,2 Dae Young Zang1,2

1Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang 14066, Republic of Korea; 2Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea

*These authors contributed equally to this work

Correspondence: Dae Young ZangDivision of Hematology-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, 22, Gwanpyeong-ro 170beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do 14068, Republic of KoreaTel +82-31-380-4167Fax +82-31-386-1528Email fhdzang@gmail.com

Purpose: CD44 isoforms are highly expressed in cancer stem cells, initiating tumor growth and sustaining tumor self-renewal. Among these isoforms, CD44 variant 9 (CD44v9) is overexpressed in chronic inflammation-induced cancer. CD44 and the mesenchymal-to-epithelial transition (MET) receptor tyrosine kinase are coactivated in some gastric cancers (GCs). In this study, we characterized MET and CD44 expression and signaling in human GC cell lines and analyzed differences in the susceptibility of these lines to foretinib.Patients and Methods: We analyzed cell viability and the rate of apoptotic cells using MTS assays and flow cytometry, respectively. Gene and protein expression were assessed by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and immunoblotting, respectively.Results: Foretinib treatment resulted in dose-dependent inhibition of growth in c-MET-amplified MKN45 and SNU620 cells with concomitant induction of apoptosis, but not in c-MET-reduced MKN28 and AGS cells. Foretinib treatment also significantly reduced phosphor-c-MET, phosphor-AKT, beta-catenin, and COX-2 protein expression in MKN45 and SNU620 cells. Interestingly, foretinib significantly reduced CD44, CD44v9, COX-2, OCT3/4, CCND1, c-MYC, VEGFA, and HIF-1a gene expression in CD44 and MET coactivated MKN45 cells and increased CD44s gene expression; in contrast, these drugs were only slightly active against SNU620 cells.Conclusion: The results of this study indicate that foretinib could be a therapeutic agent for the prevention or treatment of GCs positive for CD44v9 and c-MET.

Keywords: c-MET, CD44v9, foretinib, gastric cancer, OCT3/4

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post here:
Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferati | OTT - Dove Medical Press

Chinese New Year babys B.C. family gives gift of life in cord-blood donation – The Province

Jack Chieh and Yinnie Wong with their baby boy, born last Friday (Chinese New Year). The couple donate her baby's cord blood to the cord blood bank at B.C. Womens Hospital & Health Centre.Handout

Yinnie Wong and Jack Chiehs six-pound, 13-ounce baby boy as yet unnamed was born on an auspicious day, Jan. 24, Chinese New Year, and hes already doing good in the world.

Everyone was really happy, it is supposed to be a lucky day, said Wong.

Although the birth was a planned C-section, Wong had no control over the date hospital administrators chose for the birth. What she did have control over was the choice to donate her babys cord blood to the cord blood bank at B.C. Womens Hospital & Health Centre, which has just celebrated its fifth anniversary.

Cord blood is blood that is taken from the umbilical cord and placenta immediately after the birth of a healthy infant. Cord blood is rich in stem cells, and can be used to treat over 80 diseases, including leukemia.

According to Canadian Blood Services, ethnically diverse donors are especially needed because although Stats Canada data shows 67.7 per cent of Canadians consider their ethnic origin to be diverse, only 31 per cent of Canadians with blood in Canadas stem-cell registry are from ethnically diverse backgrounds.

Crystal Nguyen, 20, is a former B.C. Childrens Hospital patient whose life was saved by a stem-cell transplant from donated cord blood. Nguyen was first diagnosed with acute myeloid leukemia at age 12. After chemo, she went into remission for almost three years. Then the cancer returned. She was told she needed a bone-marrow transplant.

Crystal Nguyen, now 20, was first diagnosed with acute myeloid leukemia at age 12. She found a stem-cell match for a needed bone-marrow transplant through the international cord blood bank.Handout

When I relapsed I was very confused, it was kind of surreal. The main thing about being told I needed the bone-marrow stem-cell transplant was confusion, fear and anxiety.

Nguyen is of Vietnamese descent and needed a match to survive. No one in her family was a match, nor was there a stem-cell match in the Canadian cord blood bank, but a match was found thanks to the Canadian Blood Services partnerships with 47 international blood banks.

I was told it came through the international cord blood bank from somewhere very far away, said Nguyen, who has been in remission since the transplant.

When she learned the stem-cell transplant had been successful, Nguyen, who is now studying to become a pediatric oncology nurse, said it felt too good to be true.

There was a lot of happiness, joy, excitement. Donating cord blood is such a simple way to save a life.

Although cord blood can be collected and stored for a fee by private companies and reserved for the donor familys use, cord blood donated through Canadian Blood Services is available free to the public whoever needs the match.

Wong didnt hesitate when her son was born. I felt like I wanted to do it if it helps someone in the public, and if it could save lives I would have been very happy to help another child, said Wong, who is a nurse at B.C. Womens hospital.

dryan@postmedia.com

CLICK HERE to report a typo.

Is there more to this story? Wed like to hear from you about this or any other stories you think we should know about. Email vantips@postmedia.com.

Continue reading here:
Chinese New Year babys B.C. family gives gift of life in cord-blood donation - The Province

PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation…

This article was originally published here

PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma.

BMJ Open. 2020 Jan 29;10(1):e033176

Authors: McCourt O, Fisher A, Ramdharry G, Roberts AL, Land J, Rabin N, Yong K

AbstractINTRODUCTION: Myeloma, a blood cancer originating from plasma cells, is the most common indication for autologous stem cell transplantation (SCT). Patients with myeloma undergoing autologous SCT (ASCT) experience treatment-related morbidity and reduction in function and well-being for many months post-treatment. Interventions targeting physical functioning delivered prior to and during SCT have shown promising results in mixed haematological populations and may offer a non-pharmacological solution to physically optimising and preparing patients for SCT. The aim of this study is to investigate the feasibility of a physiotherapist-led exercise intervention as an integral part of the myeloma ASCT pathway at a UK tertiary centre.METHODS AND ANALYSIS: PERCEPT is a single-site, pilot randomised controlled trial of an exercise intervention embedded within the myeloma ASCT pathway, compared with usual care. The primary study end points will be feasibility measures of study and intervention delivery including recruitment rates, acceptability of intervention, study completion rate and any adverse events. Secondary end points will evaluate differences between the exercise intervention group and the usual care control group in cancer-related fatigue, quality of life, functional capacity (6min walk test; handheld dynamometry; a timed sit-to-stand test) and objective and self-reported physical activity. Outcomes will be assessed at four time points, approximately 6-8 weeks prior to SCT, on/around day of SCT, on discharge from SCT hospital admission and 12 weeks post-discharge. The exercise intervention comprises of partly supervised physiotherapist-led aerobic and resistance exercise including behaviour change techniques to promote change in exercise behaviour. The primary outcomes from the trial will be summarised as percentages or mean values with 95% CIs. Group differences for secondary outcomes at each time point will be analysed using appropriate statistical models.ETHICS AND DISSEMINATION: This study has NHS REC approval (Camden and Kings Cross, 19/LO/0204). Results will be disseminated through publication and presentations at haematology and rehabilitation-related meetings.TRIAL REGISTRATION NUMBER: ISRCTN15875290.

PMID: 32001493 [PubMed in process]

View post:
PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation...

Malcolm McGregor, 5, who is fighting cancer, returns home to hero’s welcome – Wisconsin Rapids Tribune

Malcolm McGregor, 5, has been receiving treatment in Madison for neuroblastoma and returned home Sunday for the first time in four months. 24/7 Wall Street

GRAND RAPIDS Malcolm McGregor returned home to a heros welcome Sunday.

Family and friends erupted into cheers as the 5-year-old boy pulled into his driveway for the first time in four months.The McGregor family was escorted through Kellner and back to their Grand Rapids home by emergency vehicles from the Grand Rapids Police Department, Grand Rapids Fire Department, Wood County Sheriffs Department, Wood County Sheriff's Rescue, United Ambulance and others.

Groups of well-wishers also gathered along 80th Street in Kellner to welcome him home.

Malcolm, who has been battling stage 4 high-risk neuroblastoma since Dec. 24, 2018, spent the past four months at American Family Children's Hospitaland the Ronald McDonald House in Madison after receiving his second stem cell transplant in early October. The stay was initially expected to last only four weeks, but fevers, high blood pressure, infections and other life-threatening complications extended his stay.

RELATED:4-year-old Wisconsin Rapids boy fights cancer; family asks for cards and letters

RELATED:Wisconsin Rapids' 2019 People of the Year

Autoplay

Show Thumbnails

Show Captions

His parents, Jon and Tracy McGregor, have provided near-daily updates on Malcolms health struggles and victories during the stay on the Facebook group Malcolms MARVELous SUPER HERO cancer fighters, and on Saturday morningthey shared the happy news.

Four months Malcolm has been here. He missed four holidays. He almost died. Just thinking of writing this post has me all kinds of emotional but here we go. MALCOLM IS GOING HOME! Tracy McGregor wrote.

The McGregor family first shared Malcolms story with a Wisconsin Rapids Daily Tribune reporter in January 2019 when they asked people to send superhero-, Teenage Mutant Ninja Turtles- and PAW Patrol-inspired cards and letters to the boy as he fought cancer.

Soon, packages started arriving from across the United States and countries around the world.

I cannot begin to describe what its been like getting all these cards and packages, Tracy McGregor shared last year on Facebook. Malcolm loves going to the post office to pick them up! Thank you everyone!

That support has continued throughout Malcolms ongoing treatment. Community members have contributed over $12,000 to the familys GoFundMe account, donated items to the familys Amazon Wishlist and provided meals through Meal Train.

Hundreds of people also organized, volunteered at, donated to and attended the Malcolms Marvelous Superhero Cancer Crusade fundraiser in September at Wildhorse Saloon. The event included music, childrens activities, food and basket raffles.

Malcolm McGregor, 5, his family and members of local law enforcement organizations pose for a photo after Malcolm returned to his Grand Rapids, Wisconsin, home on Sunday, Feb. 2, 2020. He has been receiving treatment in Madison for stage 4 high-risk neuroblastoma for the past four months and returned home for the first time Sunday.(Photo: Jamie Rokus/USA TODAY NETWORK-Wisconsin)

In November, two members of the Wood County Sheriffs Rescue traveled to Madison to deliver Christmas cheer and gifts to Malcolm. And many local small-business owners and individuals have held fundraisers during the past year for the family, too.

Malcolm still will have to return to Madison monthly for immunotheraphy treatment through June and by mid-summer Malcolm will be done with treatment, Tracy McGregor wrote on Facebook.

People who wish to support the family can find needed items on their Amazon Wishlist or donate money through PayPal or GoFundMe.

Read or Share this story: https://www.wisconsinrapidstribune.com/story/news/crime/2020/02/02/malcolm-mcgregor-wisconsin-rapids-who-fighting-neuroblastoma-cancer-returns-home-heros-welcome/4640466002/

Continued here:
Malcolm McGregor, 5, who is fighting cancer, returns home to hero's welcome - Wisconsin Rapids Tribune

4 Crazy but Effective Ways to Save More Money This Year – Nasdaq

It's no secret that Americans aren't doing all that well in the savings department. An estimated 39% of U.S. adults don't have the money on hand to cover a $400 emergency, and 45% of Americans have no money earmarked for retirement savings.

If your savings efforts have been far from fruitful in recent years, it's time to do better -- even if that means going to a bit of an extreme to get there. Here are a few far-out but effective methods of boosting your savings -- and buying yourself the financial security you're currently missing.

IMAGE SOURCE: GETTY IMAGES.

If you're not familiar with no-spend periods, they involve not forking over so much as a dime on non-essentials for different periods of time. It's common to have an occasional no-spend week or no-spend month, but if you're really intent on boosting your savings, you may want to extend that restriction for a full year. That's right -- no restaurant meals, non-work clothing, or paid entertainment for an entire 12 months.

Will that be difficult? Absolutely. But imagine you currently spend $600 a month on dining out, leisure, apparel, and other items you enjoy having but can technically live without. In the course of a year, you'll be $7,200 richer.

Housing is the typical American's greatest monthly expense, so if you're able to reduce it substantially, you're apt to boost your savings in a very meaningful way. Imagine you currently rent a three-bedroom, 2000-square-foot apartment with your spouse and child for $2,000 a month. If you were to downsize to a one-bedroom (yes, you read that correctly) that takes up 800 square feet, you might reduce your rent to $1,000.

Will living in cramped quarters for a year be easy? Not at all. But if it saves you $12,000, it's a sacrifice worth making.

It costs $9,282 a year, on average, to own a vehicle, according to AAA. If you're willing to give yours up, you could wind up banking that much cash in the course of a year instead.

Now if you live in an area where public transportation is abundant, that's not such a huge ask. But if you live in suburbia, it could prove more challenging. That doesn't mean it can't be done, though. You could consider carpooling with your spouse (meaning, downsize from a two-car household to a single car), catching rides with friends or colleagues, or biking to and from work if that's a reasonable thing to do (if your office is 40 miles away, it's not).

Will giving up a car limit you logistically and socially? Probably. But think about it this way -- if it's harder to get around, you may be less inclined to dine out or spend money on entertainment, which will help your savings efforts.

The typical American spends $3,456 a year on restaurant meals and food outside the home, according to the U.S. Bureau of Labor Statistics. But restaurants generally charge a 300% markup on the items they serve, which means that if your spending is in line with the typical American's, you could save yourself close to $2,600 in the course of a year by cooking every meal you eat at home.

Will that constitute a time investment? It sure will. But you never know -- you may discover that you enjoy cooking your own food, and that doing so is healthier for you anyway.

If you're doing reasonably well financially -- meaning, you're on track for retirement and have a healthy emergency fund -- then there's certainly no need to go to any of the above extremes (unless, of course, you happen to love a good challenge). But if your near-term and long-term savings are virtually nonexistent, then you may need to take drastic measures to build them up. The good news? You don't need to commit to these extremes for a lifetime. Make any of the above moves for a single year, and your savings could easily take a turn for the much improved.

The $16,728 Social Security bonus most retirees completely overlook If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income. For example: one easy trick could pay you as much as$16,728 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after.Simply click here to discover how to learn more about these strategies.

The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More:
4 Crazy but Effective Ways to Save More Money This Year - Nasdaq

Patient in Japan 1st to have iPS cell heart muscle transplant : The Asahi Shimbun – Asahi Shimbun

A patient who received the worlds first transplant of cardiac muscle cells using artificially derived stem cells known as iPS cells this month is in stable condition, an Osaka University team said Jan. 27.

After surgery, doctors closely monitored the patient, who had ischemic cardiomyopathy, a condition in which clotted arteries cause heart muscles to malfunction. But the patient has been moved toa general hospital ward, the team said.

Yoshiki Sawa, a professor of cardiovascular surgery at the university, who led the team that conducted the transplant, said the team aims to put the technique into practical use.

Sawa said the team hopestransplants of heart muscle tissues derived from induced pluripotent stem cellswill be used to save many patients who have heart conditions.

In the clinical trial, three sheets of heart muscle tissues made from iPS cells stocked at Kyoto Universitys Center for iPS Cell Research and Application were attached to affected parts of the patients heart. The iPS cells were created from tissues provided by a healthy donor.

The sheets were 4 to 5 centimeters in diameter and 0.1 millimeter thick.

The transplant's goal is to regenerate cardiac blood vessels using a substance secreted by the sheets of muscle cells. The sheets are degradable and disappear from the body several months after they secrete the substance, according to the team.

The university plans to perform similar transplants on nine other patients who have serious heart problems.

The Osaka University team had planned to conduct the clinical trial of the transplant earlier after the government approved the plan in May 2018.

But it was postponed due to damage from a powerful earthquake that hit Osaka Prefecture the following month that rendered its facility to cultivate cells unusable.

The trial is part of the process toward the future distribution of medical products using cells.

Osaka Universitys announcement of the successful transplant of tissues created from iPS cells marked the fourth such transplantation.

Including Osaka University's trial, Japanese surgeons have now successfully transplanted tissues created from iPS cells four times.

The world's first transplant of iPS-derived cells was conducted in 2014 whenthe Riken research institute transplanted retina cells for a patient with age-related macular degeneration.

In 2018, Kyoto University transplanted nerve cells for a Parkinson disease patient. Osaka University transplanted cornea cells into a patient with a disease of the cornea in 2019.

Patients who undergo transplants using iPS-derived cell must accept the risk that the cells may become cancerous.

The moreiPS-derived cells a patient receives, the higher their risk.

Hundreds of thousands of retina cells were used in the 2014 retina transplant. In the 2018 and 2019 transplants, the number of nerve and cornea cells used soared to between 5 million to 6 million.

Osaka University's latest transplant utilized roughly 100 milliontissues made from iPS cells.

Sawa acknowledged the transplanted heart muscle tissues could turn cancerous, but said the teamhas made great efforts to remove potentially cancerous cells.

Hideyuki Okano, professor of molecular neurobiology at Keio University, who is researching the application of iPS-derived nerve cells to treat patients with spinal cord damage, said the risk was worth it.

Okano said the Osaka University's transplant, using tissues made from iPS cells from a donor, could be more effective than the existing therapy, which uses the patients own muscle tissues.

I understand that the transplanted tissues might become cancerous or cause an erratic heart rhythm, but the transplantation of the iPS-derived heart muscle tissues can be more effective than muscle tissue sheets made from the patients leg, Okano said.

Keio University is also planning to conduct clinical research using iPS-derived cells to regenerate heart tissues.

The rest is here:
Patient in Japan 1st to have iPS cell heart muscle transplant : The Asahi Shimbun - Asahi Shimbun

Outlook on the Gene Therapy for CNS Disorders Market to 2025 by Application, – News by aeresearch

New Market Research Report on Gene Therapy for CNS Disorders Market size | Industry Segment by Applications (Hospitals, Clinics and Others), by Type (Ex Vivo and In Vivo), By Regional Outlook - Global Industry Analysis, Size, Share, Growth, Opportunity, Latest Trends, and Forecast to 2025.

Regional analysis is another highly comprehensive part of the research and analysis study of the global Gene Therapy for CNS Disorders market presented in the report. This section sheds light on the sales growth of different regional and country-level Gene Therapy for CNS Disorders markets. For the historical and forecast period 2020 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Gene Therapy for CNS Disorders market.

This report on Gene Therapy for CNS Disorders Material Market delivers an in-depth analysis that also comprises an elaborate assessment of this business. Also, segments of the Gene Therapy for CNS Disorders Material market have been evidently elucidated in this study, in addition to a basic overview pertaining to the markets current status as well as size, with respect to the profit and volume parameters.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/64581

Global market focusing on major players of Gene Therapy for CNS Disorders market:

This Gene Therapy for CNS Disorders Market Research/analysis Report Contains Answers to your following questions:

Market segmentation, by product types:

Market segmentation, by applications:

Highlights of Report:

An all-inclusive framework of the geographical terrain:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/64581

Read more here:
Outlook on the Gene Therapy for CNS Disorders Market to 2025 by Application, - News by aeresearch

"The results amazed both the doctors and ourselves" – first patient to receive pioneering cancer treatment at MRI – Manchester Evening News

A year ago Janice Baker's future seemed bleak.

A second bout of chemotherapy in February 2019 had failed to erase her cancer.

She was so weak she could not walk.

Janice, from Romiley in Stockport, had been diagnosed with large B-cell lymphoma a type of cancer of the blood and lymph glands in April 2018 after feeling unwell for several months.

But now, she has the vim and energy to look after her grandchild after a remarkable response to a pioneering treatment.

CAR-T cell therapy helps to genetically reprogramme a person's immune system to help them fight cancer.

Janice was the first patient to undergo the therapy at Manchester Royal Infirmary (MRI).

Manchester University NHS Foundation Trust (MFT) was named as one of a very small number of centres in the UK to offer the revolutionary new treatment, widely regarded as the most exciting cancer treatment development in decades, in 2018.

Janice underwent two separate bouts of chemotherapy in August 2018 and February 2019, which didnt manage to successfully treat the cancer.

It was then she was offered CAR-T therapy.

Janice, who was diagnosed with the cancer in the same week her husband Chris was diagnosed with prostate cancer, said; Over the last 18 months my health was very up and down. At my worst I could barely get out of bed. I had to use a wheelchair, lost a lot of weight and hardly left the house, except for hospital appointments.

When I heard I was eligible for CAR-T cell treatment I was thrilled as I had read up about the amazing results and it felt like a real lifeline. My chemotherapy had limited success which was unfortunate but did mean that I was a bit stronger to face the CAR-T treatment.

The treatment itself was actually quite straightforward. The removal and replacement of cells is not that intrusive, and the wonderful staff were very attentive and kept a very close eye on me. There can be a few side effects but, fortunately, I had very few problems and the after effects were quite minimal.

Janice had the CAR-T treatment in May 2019 and was an inpatient for a couple of weeks at the MRI before returning home.

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a personalised medicine used to treat patients with certain types of leukaemia and lymphoma.

It is a highly complex new type of immunotherapy which involves collecting and using the patients own immune cells to target their cancer in a process which is completed over a number of weeks.

Janice added; After two weeks I was feeling encouraged that everything was going well. I was still quite poorly and it has been a long slog but I have slowly been building up my strength.

I had a scan in August, which we hoped would show a significant decline in the cancer, but the results amazed both the doctors and ourselves, as it showed that the cancer cells seem to have gone completely.

Things are now getting back to normal. I have been on holiday, am back to driving my car and, best of all, I have the energy to look after my Grandson. I really feel like I have the opportunity to start planning for the future again.

I had another PET scan in November 2019, which was also clear, so I am feeling really optimistic now.

Dr Eleni Tholouli, Consultant Haematologist and Director of the Adult Stem Cell Transplant and CAR-T Therapy Unit at Manchester Royal Infirmary, and who has been involved in Janices care throughout, said: We are delighted for Janice and her family that she has responded so well to CAR-T therapy. This is a ground-breaking new treatment for adult cancer patients at the MRI which uses the patients own immune cells, allowing us to create a powerful medicine tailored to an individuals needs.

So to see Janice have these incredible results in such a short space of time is really encouraging. This reassures us that we have to continue all the hard work and make this therapy available to more patients.

View post:
"The results amazed both the doctors and ourselves" - first patient to receive pioneering cancer treatment at MRI - Manchester Evening News

Lochaber cyclist pledges to cycle from London to Paris in aid of charity – Press and Journal

When David Wilsons spine snapped, leading to a cancer diagnosis, there were fears he would be left paralysed.

But the cyclist and mountaineer had his back rebuilt and went through gruelling chemotherapy and now, just a year later, he is planning a very physical challenge to raise funds for charity,

The Fort William man, who is 60, has journeyed across the globe to the far reaches of the Himalayas, Greenland, Norway and New Zealand. And now he is cycling from London to Paris.

In the summer of 2018, he was cycling the Great Divide Mountain Bike Trail a 3,083-mile off-road ride from Canada to Mexico when his back began to hurt.

He cut the trip short, putting his injury down to old age and wear and tear.

And in February last year his spine suddenly snapped due to a form of blood cancer called Multiple Myeloma.

Following his devastating diagnosis, Mr Wilson owner of the Limetree Hotel, restaurant and art gallery in Fort William was transferred to hospital in Glasgow where he underwent surgery to rebuild his spine.

He explained: I was taken from the Belford Hospital to Inverness, then transferred from Inverness to Glasgow to the surgeons there and they were able to rebuild my spine by putting in a scaffolding in my back with titanium and screws. That stage was touch and go on whether I would be paraplegic now and being an outdoors geezer I was pretty fed up about that.

Following a successful surgery, the visual artist began to slowly walk again before enduring a rigorous six month cycle of chemotherapy to attack the disease.

On September 20, he then received a stem cell transplant, giving him a new lease of life.

The father-of-two said: I had a very adventurous life.

I have been in situations where death has been very close to me, people have been killed right next to me but I have always felt there was a way in those situations that you could get out of them but with cancer like this particular cancer there is no escape. Youre in the hands of the disease and you have to take your chances when you get them.

Now in remission, Mr Wilson is aiming to defy the odds by cycling 500km from London to Paris in September, arriving in Paris exactly a year following his stem cell treatment.

He has now launched a Just Giving page in the hopes of raising 1,500 for Myeloma UK towards finding a cure for the crippling disease.

Multiple myeloma, also known simply as Myeloma, is a form of blood cancer arising from plasma cells causing problems to various areas of the body such as the spine, skill, pelvis and ribs.

It develops in abnormal plasma cells, which release a large amount of a single type of antibody known as paraprotein which has no useful function.

Myeloma affects where bone marrow is normally active in an adult, such as in the bones of the spine, skull, pelvis, the rib cage, long bones of the arms and legs and the areas around the shoulders and hips.

Each year in the UK, approximately 5,700 people are diagnosed with myeloma.

Myeloma mainly affects those over the age of 65, however it has been diagnosed in people much younger.

In the early stages of developing the disease, patients rarely experience side effects and is only diagnosed through routine blood or urine tests.

As the disease progresses, the cancer can cause a range of problems including aches and tender areas in your bones, causes bones to break and fracture easily, kidney problems and repeated infections.

Patients can also become lethargic, weak and short of breath caused as a result of anaemia.

In most diagnosed cases of myeloma it cannot be cured, however, treatment can be given to control the condition and minimise its effects for several years.

Treatment includes anti-myeloma medicines to destroy the cancer cells or control the cancer if patients suffer a relapse as well as a range of medicines to prevent or treat side effects of myeloma.

Read more:
Lochaber cyclist pledges to cycle from London to Paris in aid of charity - Press and Journal

Snake venom can now be made in a lab and that could save many lives – WPMT FOX 43

If youre unlucky enough to have a poisonous snake sink its fangs into you, your best hope is an antivenom, which has been made in the same way since Victorian times.

It involves milking snake venom by hand and injecting it into horses or other animals in small doses to evoke an immune response. The animals blood is drawn and purified to obtain antibodies that act against the venom.

Producing antivenom in this way can get messy, not to mention dangerous. The process is error prone, laborious and the finished serum can result in serious side effects.

Experts have long called for better ways to treat snake bites, which kill some 200 people a day.

Now finally scientists are applying stem cell research and genome mappingto this long-ignored field of research. They hope it will bring antivenom production into the 21st Century and ultimately save thousands, if not hundreds of thousands, of lives each year.

Researchers in the Netherlandshave created venom-producing glands from the Cape Coral Snake and eight other snake species in the lab, using stem cells. The toxins produced by the miniature 3-D replicas of snake glands are all but identical to the snakes venom, the team announced Thursday.

In a parallel breakthrough, scientists in India have sequenced the genome of the Indian cobra,one of the countrys big four snakes that are responsible for most of the50,000 snakebite deaths India sees a year.

Theyve really moved the game on, said Nick Cammack, head of the snakebite team at UK medical research charity Wellcome. These are massive developments because its bringing 2020 science into a field thats been neglected.

Hans Clevers, the principal investigator at the Hubrecht Institute for Developmental Biology and Stem Cell Research in Utrecht, never expected to be using his lab to make snake venom.

A decade ago,he invented the technique to make human organoids miniature organs made from the stem cells of individual patients. Theyve allowed doctors to test the specific effects of drugs safely outside the body, something that has revolutionized and personalized areas such as cancer treatment.

So why did he decide to culture a snake venom gland?

Clevers said it was essentially a whim of three PhD students working in his lab whod grown bored of reproducing mouse and human kidneys, livers and guts. I think they sat down and asked themselves what is the most iconic animal we can culture? Not human or mouse. They said its got to be the snake. The snake venom gland.

They assumed that snakes would have stem cells the same way mice and humans have stems cells but nobody had ever investigated this, said Clevers.

After sourcing some fertilized snake eggs from a dealer, the researchers found they were able to take a tiny chunk ofsnake tissue,containing stem cells, and nurture it in a dish with the same growth factor they used for human organoids albeit at a lower temperature to createthe venom glands. And they found that these snake organoids tiny balls just one millimeter wide produced the same toxins as the snake venom.

Open them up and you have a lot of venom. As far as we can tell, its identical. Weve compared it directly to the venom from the same species of snake and we find the exact same components, said Clevers, who was an author of the paper that published in thejournal Celllast week.

The team compared their lab-made venom with the real thing at the genetic level and in terms of function, finding that muscle cells stopped firing when exposed to their synthetic venom.

The current antivenoms available to us, produced in horses not humans, trigger relatively high rates of adverse reactions, which can be mild, like rash and itch, or more serious, like anaphylaxis. Its also expensive stuff. Wellcome estimate that one vial of antivenom costs $160, and a full course usually requires multiple vials.

Even if the people who need it can afford it most snakebite victims live in rural Asia and Africa the world has less than half of the antivenom stock it needs, according to Wellcome.Plus antivenoms have been developed for only around 60% of the worlds venomous snakes.

In this context, the new research could have far-reaching consequences, allowing scientists to create a biobank of snake gland organoids from the 600 or so venomous snake species that could be used to produce limitless amounts of snake venom in a lab, said Clevers.

The next step is to take all that knowledge and start investigating new antivenoms that take a more molecular approach, said Clevers.

To create an antivenom, genetic information and organoid technology could be used to make the specific venom components that cause the most harm and from them produce monoclonal antibodies, which mimic the bodys immune system, to fight the venom, a method already used in immunotherapy treatments for cancer and other diseases.

Its a great new way to work with venom in terms of developing new treatments and developing antivenom. Snakes are very difficult to look after, Cammack said, who was not involved with the research.

Clevers said his lab now plans to make venom gland organoids from the worlds 50 most venomous animals and they will share this biobank with researchers worldwide. At the moment, Clevers said they are able to produce the organoids at a rate of one a week.

But producing antivenomis not an area that pharmaceutical companies have traditionally been keen to invest in,Clevers said

Campaigners often describe snakebites as a hidden health crisis, with snakebites killing more people than prostrate cancer and choleraworldwide, Cammack said.

Theres no money in the countries that suffer. Dont underestimate how many people die. Sharks kill about 20 per year. Snakes kill 100,000 or 150,000, said Clevers.

Im a cancer researcher essentially and I am appalled by the difference in investment in cancer research and this research.

One challenge to making synthetic antivenom is the sheer complexity of how a snake disables its prey. Its venom contains several different components that have different effects.

Researchers in India have sequenced the genome of the Indian Cobra, in an attempt to decode the venom.

Published in thejournal Nature Geneticsearlier this month,its the most complete snake genome assembled and contains the genetic recipe for the snake venom, establishing the link between the snakes toxins and the genes that encode them. Its not a straightforward cocktail the team identified 19 genes out of 139 toxin genes as the ones responsible for causing harm in humans.

Its the first time a very medically important snake has been mapped in such detail, said Somasekar Seshagiri, president of SciGenom Research Foundation, a nonprofit research center in India.

It creates the blueprint of the snake and helps us get the information from the venom glands. Next, his team will map the genomes of the saw-scaled viper, the common krait and the Russells viper the rest of Indias big four.This could help make antivenom from the glands as it will be easier to identify the right proteins.

In tandem, both breakthroughs will also make it easier to discover whether some of the potent molecules contained in snake venom are themselves worth prospecting as drugs allowing snakes to make their mark on human health in a different way to how nature intended by saving lives.

Snake venom has been used to make drugsthat treat hypertension (abnormally high blood pressure) and heart conditions such as angina.

As well as being scary, venom is amazingly useful, Seshagari said.

Follow this link:
Snake venom can now be made in a lab and that could save many lives - WPMT FOX 43